Korea Institute of Science and Technology

Seoul National University

Korea University Research and Business Foundation

Amorepacific Corporation

Ju Hee Ryu

Ick Chan Kwon

Kwangmeyung Kim

Hong Yeol Yoon

Man Kyu Shim

Jin Woong Kim

Yong Jin Kim

Jeewon Lee

Ih Seop Chang

Jun Oh Kim

In San Kim

Kwang Meyung Kim

Sang Yoon Kim

Bo Ram Lee

Jong Won Shim

Young-Ji Ko

Jae Won Lee

Nam-Hyuk Cho

Eun-Jeong Yang

Hye-Sun Kim

Ho Kyung Ko

Eun Sung Jun

Suah Yang

A probe for measuring the activity of caspase-1 according to the present disclosure can specifically image cells or tissues where inflammatory response is induced because it is cleaved by reacting specifically with the active caspase-1 enzyme in vivo and in vitro and re-emits fluorescence. The probe for measuring the activity of caspase-1 can be used for various purposes, such as for imaging of cells or tissues where inflammatory response is induced, as a drug carrier, for screening of a drug inhibiting inflammatory response, etc. The probe for measuring the activity of caspase-1 is applicable both in vivo and in vitro, and can be used for various applications such as high-throughput screening for new drug development, early diagnosis of diseases, etc.

Probe for measuring activity of Caspase-1 and composition for diagnosis of inflammatory diseases containing same

The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues. In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.

Pharmaceutical composition for combination therapy for preventing or treating cancer containing tumor-specific drug conjugate and anti-PD-L1 antibody as active ingredients

The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.

Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same

The present invention relates to a protein nanoparticle having a surface on which a cancer-specific epitope is fused and expressed, a method for producing the same, and a composition for cancer immunotherapy containing the protein nanoparticle as an active ingredient, and more specifically, to a recombinant microorganism into which a vector in which a promoter, a gene of a human ferritin heavy chain protein, and a gene encoding the cancer-specific epitope are operably linked is introduced, a protein nanoparticle in which a cancer-specific epitope is fused and expressed on a surface of the human ferritin heavy chain protein, a method of producing the protein nanoparticle, and a composition for cancer immunotherapy including the protein nanoparticle as the active ingredient, wherein the cancer-specific epitope on the surface of the protein nanoparticle according to the present invention is able to be expressed with correct orientation and high density, and the composition for cancer immunotherapy including the protein nanoparticle as the active ingredient has significantly excellent cancer immunotherapeutic effect as compared to the existing nanoparticle-based composition.

Protein nanoparticle linked with cancer specific epitope and composition for cancer immunotherapy comprising the same

Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity.

Drug-fluorophore complex for specific detection of tumor cells

Disclosed herein are cationic polymer nanocapsules encapsulating an oil-soluble active ingredient, and a cosmetic composition containing the same. The cationic polymer nanocapsules have a molecular weight of 5,000-100,000, a surface potential of 5-100 mV and a particle size of 50-500 nm. Also, disclosed is a cosmetic composition containing said cationic polymer nanocapsules.

Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same

Growing community of inventors

Seoul, South Korea

Ju Hee Ryu